( CHICAGO--(BUSINESS WIRE)--Jun 4 2007 -...)New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting,Health

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Cytogen Corporation (NASDAQ: CYTO) today reported results from clinical trials demonstrating that QUADRAMET (samarium Sm-153 lexidronam injection) can be safely administered to prostate cancer patients who are also receiving the chemotherapy docetaxel (Taxotere(R), Sanofi-Aventis). Clinical data also support further evaluation of the combination regimen for the treatment of prostate cancer in a Phase 2 program. The results were presented and/or published at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, Illinois and are summarized herein.

ASCO Abstracts

"Phase 1 study of docetaxel and (153)Sm-lexidronam repetitively administered for castrate metastatic prostate cancer" by Morris M.J. et al. Memorial Sloan-Kettering Cancer Center (Abstract No. 5152, Poster No. L6)

Despite a favorable safety and efficacy profile, the routine and repetitive use of QUADRAMET for the palliation of pain from cancer that has spread to the bone has historically been limited in combination settings due to concerns regarding the potential for overlapping toxicities.

Accordingly, the objective of this open-label Company-sponsored Phase 1 study was to evaluate the safety and feasibility of repetitive co-administration of docetaxel and QUADRAMET in twenty-eight hormone-refractory prostate cancer patients with progressive disease and at least three bone metastases confirmed through a bone scan. In addition, early clinical data suggest synergistic effects between QUADRAMET and chemotherapy; therefore, as a secondary objective the anti-tumor effects of the combined regimen were also assessed.

Patients received repeated escalating doses of the combination of QUADRAMET (at doses up to the full FDA-approved doses of 1.0 mCi/kg, given every six to nine weeks) and docetaxel (at doses up to 75 mg/m2 given every three weeks). Dose
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
2. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
3. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
4. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
5. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
6. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
7. VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting
8. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
9. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
10. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting